Ceribell, Inc.
CBLL Nasdaq· Electromedical & Electrotherapeutic Apparatus
Last close · Oct 26, 2026
$27.03
KIRA · Stoqly’s AI analyst, in plain words
- Ceribell, Inc. had $89.1M of revenue in fiscal 2025, up 36.1% on the year before.
- Its operating margin was −65.6%, down 4.9 pts: of every 100 in sales, about −66 is left after running the business.
- Ceribell, Inc. lost $53.4M in fiscal 2025.
- Free cash flow was −$41.6M in fiscal 2025, −46.7% of revenue.
Market cap
$1.0B
P/E
—
Revenue
$89.1M
Net income
−$53.4M
Free cash flow
−$41.6M
Operating margin
−65.6%
Ceribell, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+36.1%
Yes. Sales grew 36.1% last year.
Does it make a profit?
−60.0%
No. It lost money last year.
Does profit turn into cash?
−46.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Ceribell, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Ceribell, Inc.
- CIK
- 0001861107
Ceribell, Inc. · CBLL
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $45.2M | $65.4M | $89.1M |
| Revenue growth | — | 44.7% | 36.1% |
| Gross margin | 84.4% | 86.7% | 87.9% |
| Operating margin | −66.4% | −60.7% | −65.6% |
| Net income | −$29.5M | −$40.5M | −$53.4M |
| Net margin | −65.1% | −61.8% | −60.0% |
| Diluted EPS | −$5.56 | −$3.39 | −$1.46 |
| Cash | |||
| Cash from operations | −$29.2M | −$35.0M | −$40.8M |
| Capital expenditure | $1.0M | $1.3M | $0.8M |
| Free cash flow | −$30.1M | −$36.4M | −$41.6M |
| FCF margin | −66.6% | −55.6% | −46.7% |
| Share count change | — | 125.3% | 205.8% |
| Debt and strength | |||
| Cash and short-term investments | $34.5M | $194M | $159M |
| Shareholders' equity | −$112M | $191M | $155M |
| Current ratio | 2.4x | 16.7x | 9.7x |
| Interest coverage | −14.3x | −19.9x | −30.9x |
| Returns and quality | |||
| Return on equity | — | −102.5% | −30.8% |
| Return on tangible equity | — | −21.2% | −34.4% |
| Piotroski F-score | — | 4 | 3 |
| Altman Z'' | −12.0 | 8.2 | 4.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$22.9M
10 insiders
Of sales under plans
78%
$17.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ceribell, Inc. · CBLL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $27.03 a share, the company is worth $1.0B.
Source: SEC EDGAR XBRL filings (CIK 0001861107). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.